<DOC>
	<DOCNO>NCT01822015</DOCNO>
	<brief_summary>This pilot clinical trial study sirolimus , idarubicin , cytarabine treat patient newly diagnose acute myeloid leukemia . Sirolimus may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , idarubicin cytarabine , work different way stop growth cancer cell , either kill cell stop divide . Giving sirolimus together idarubicin cytarabine may kill cancer cell .</brief_summary>
	<brief_title>Sirolimus , Idarubicin , Cytarabine Treating Patients With Newly Diagnosed Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : 1 ) To determine whether association baseline mammalian target rapamycin ( mTOR ) activation pair mTOR target inhibition post-treatment leukemic blast clinical response patient newly diagnose acute myeloid leukemia ( AML ) treat sirolimus idarubicin/cytarabine . SECONDARY OBJECTIVES : 1 . To estimate response rate sirolimus idarubicin/cytarabine patient newly diagnose AML compare historical data use idarubicin/cytarabine alone . 2 . To determine ability oral sirolimus inhibit mTOR leukemic blast . 3 . To assess mTOR pathway inhibition correlate clinical response . 4 . To collect information safety , tolerability , efficacy sirolimus combination idarubicin/cytarabine patient newly diagnose AML . 5 . To describe progression-free survival overall survival ( 1 year , 2 year 5 year ) patient treat sirolimus idarubicin/cytarabine . OUTLINE : Patients receive sirolimus orally ( PO ) daily ( QD ) day 1-10 , idarubicin intravenously ( IV ) 3-5 minute day 4-6 , cytarabine IV continuously 24 hour day 4-10 . After completion study treatment , patient follow every 3 month 5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>1 . Patients must histologic evidence newly diagnose acute myeloid leukemia ( nonM3 AML ) document presence &gt; 20 % myeloid blast bone marrow 2 . Subjects must 18 year age &lt; = 60 3 . Subjects must ECOG performance status 2 less . ( see attachment 1 ) . 4 . Subjects must life expectancy least 4 week . 5 . Subjects must able consume oral medication . 6 . Required initial laboratory value : Creatinine 2.0mg/dL ; total direct bilirubin 1.5mg/dL ; SGPT ( ALT ) 3xULN ( due leukemia ) ; negative pregnancy test woman childbearing potential . 7 . Patients must able sign consent willing able comply schedule visit , treatment plan laboratory testing . 8 . Subjects must leave ventricular ejection fraction ( LVEF ) &gt; /= 45 % . 1 . Subjects APL FAB M3 ( ( 15 ; 17 ) ( q22 ; q21 ) [ PMLRAR ] eligible 2 . Subjects must receive chemotherapeutic agent AML ( except Hydroxyurea ) . Intrathecal ARAC intrathecal methotrexate permissible ( systemic isolated central nervous system ) . 3 . Subjects must receive growth factor , except erythropoietin . 4 . Subjects `` currently active '' second malignancy , nonmelanoma skin cancer eligible . 5 . Subjects uncontrolled high blood pressure , unstable angina , symptomatic congestive heart failure , myocardial infarction within past 6 month serious uncontrolled cardiac arrhythmia eligible . 6 . Subjects take follow eligible : 1 . Carbamazepine ( e.g. , Tegretol ) 2 . Rifabutin ( e.g. , Mycobutin ) 3 . Rifampin ( e.g. , Rifadin ) 4 . Rifapentine ( e.g. , Priftin ) 5 . St. John 's wort 6 . Clarithromycin ( e.g. , Biaxin ) 7 . Cyclosporine ( e.g . Neoral Sandimmune ) 8 . Diltiazem ( e.g. , Cardizem ) 9 . Erythromycin ( e.g. , AkneMycin , EryTab ) 10 . Itraconazole ( e.g. , Sporanox ) 11 . Ketoconazole ( e.g. , Nizoral ) 12 . Telithromycin ( e.g. , Ketek ) 13 . Verapamil ( e.g. , Calan SR , Isoptin , Verelan ) 14 . Voriconazole ( e.g. , VFEND ) 15 . Tacrolimus ( e.g . Prograf ) 7 . Subjects take fluconazole , voriconazole , itraconazole , posaconazole , ketoconazole within 72 hour study entry eligible . Reinstitution fluconazole , voriconazole , itraconazole , posaconazole , ketoconazole diltiazem permissible 72 hour last dose sirolimus . 8 . Subjects require HIV protease inhibitor AIDSrelated illness 9 . Subjects severe concurrent disease judgment investigator would make patient inappropriate entry study ineligible . 10 . Subjects must pregnant breastfeeding . Pregnancy test must obtain female childbearing potential . Pregnant lactate patient ineligible study due unknown human fetal teratogenic toxicity sirolimus . Males female reproductive age may participate unless agree use effective contraceptive method . 11 . Subjects uncontrolled infection eligible . Patients must active infection control . Fungal disease must stable least 2 week study entry . 12 . Subjects bacteremia must document negative blood culture prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>